bufalin
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 6, 2022 (NCT05503693)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06666283 | Phase 1 | Nov 5, 2024 | Alebund Pharmaceuticals, Peking University |
| NCT06308523 | Phase 1 | Mar 18, 2024 | Alebund Pharmaceuticals |
| NCT05503693 | Phase 1 | Dec 6, 2022 | Alebund Pty Ltd, Nucleus Network Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alebund Pharmaceuticals | For profit | 2 | 2 | 1 | 2024 |
| Alebund Pty Ltd | For profit | 1 | 1 | 1 | 2022 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1